Jill Roberts Center for Inflammatory Bowel Disease

Publications

Found 10 results

Filters: Author is Lukin, Dana [Clear All Filters]

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

D

Kumar A, Lukin D, Battat R, Schwartzman M, Mandl LA, Scherl E, Longman RS. 2020. Defining the phenotype, pathogenesis and treatment of Crohn's disease associated spondyloarthritis.. J Gastroenterol. 55(7):667-678.

Dulai PS, Boland BS, Singh S, Chaudrey K, Koliani-Pace JL, Kochhar G, Parikh MP, Shmidt E, Hartke J, Chilukuri P et al.. 2018. Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.. Gastroenterology. 155(3):687-695.e10.

Dulai PS, Singh S, Casteele NVande, Meserve J, Winters A, Chablaney S, Aniwan S, Shashi P, Kochhar G, Weiss A et al.. 2020. Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis.. Clin Gastroenterol Hepatol. 18(13):2952-2961.e8.

Agrawal M, Cohen-Mekelburg S, Kayal M, Axelrad J, Galati J, Tricomi B, Kamal K, Faye AS, Abrudescu P, Scherl E et al.. 2019. Disability in inflammatory bowel disease patients is associated with race, ethnicity and socio-economic factors.. Aliment Pharmacol Ther. 49(5):564-571.

I

Kayal M, Ungaro RC, Riggs A, Kamal K, Agrawal M, Cohen-Mekelburg S, Axelrad J, Faye A, Scherl E, Lawlor G et al.. 2021. Ileal Pouch Anal Anastomosis for the Management of Ulcerative Colitis Is Associated With Significant Disability.. Clin Gastroenterol Hepatol.

Battat R, Lukin D, Scherl EJ, Pola S, Kumar A, Okada L, Yang L, Jain A, Siegel CA. 2021. Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease.. Inflamm Bowel Dis. 27(9):1443-1451.

Agrawal M, Zhang W, Lukin D. 2019. Intestinal Spirochetosis Resembles Inflammatory Bowel Disease in a Patient With HIV Infection.. Clin Gastroenterol Hepatol. 17(6):e60.

P

Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliani-Pace JL, Hirten R, Faleck D, Barocas M et al.. 2018. Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.. Inflamm Bowel Dis. 24(11):2461-2467.

S

Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland BS et al.. 2019. Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.. Clin Gastroenterol Hepatol. 17(12):2497-2505.e1.

V

Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L et al.. 2018. Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.. Am J Gastroenterol. 113(9):1345.